Outcomes of patients with COVID-19 in the intensive care unit: A national observational study (Mexico COVID-19 ICU study)

As of 23 March 2020, a cumulative total of 332,930 confirmed cases of coronavirus disease 2019 (COVID-19) were reported in 189 countries and territories worldwide. As of this time, there had been 367 total confirmed cases of COVID-19, including four deaths in Mexico. The clinical manifestations of patients with COVID-19 are wide, asymptomatic infection, mild upper respiratory tract illness, and approximately 5% of critically ill patients with COVID-19 have presented rapidly progressive respiratory failure, development of acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) admission. On March 24, 2020, the Secretary of Health of Mexico, formally declared the beginning of phase 2. It has been estimated that many confirmed cases of COVID-19 will occur, thus resulting in a significant increase in hospital and ICU admissions.

Observational; Cross-sectional cohort study

Primary Outcome Measures  :

• Hospital mortality [ Time Frame: 30 days ]
• Mortality 30 days following hospital admission

Secondary Outcome Measures  :

• Length of stay in the intensive care unit [ Time Frame: Through study completion, an average of 30 days ]
• The number of calendar days from the day of admission (counted as 1 day) to day of intensive care unit discharge

ClinicalTrials.gov Identifier: NCT04336345

Monitoring & Evaluation
Vulnerable Populations

Apr 2020 — May 2020

Mexico

Clinical Epidemiology of COVID-19 in Malaria Settings